To the Editor: The recent article by Chapman et al1 and a case report published some years previously in the Journal2 indicated that hyponatraemia may occur during indapamide therapy. However, it should be noted that the data came from spontaneous adverse drug reaction reporting, and therefore can give no indication of the incidence or relative risk of hyponatraemia compared with other diuretics. Nor can it give the incidence of hyponatraemia as a proportion of side effects occurring during indapamide therapy.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Chapman D, Hanrahan R, McEwen J, Marley JE. Hyponatraemia and hypokalaemia due to indapamide. Med J Aust 2002; 176: 19-21.
- 2. Read SJ, Trenerry HM, Whiting GF. Hyponatraemia and raised creatine kinase level associated with indapamide. Med J Aust 1994; 161: 607-608.
- 3. Woodhead M. TGA issues advice on indapamide. Aust Doctor 2002; 8 Mar: 7.
- 4. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
- 5. Plante GE, Dessuranult DL. Hypertension in elderly patients. A comparative study between indapamide and hydrocholorothiazide. Am J Med 1988; 84: 98-103.
- 6.
- 7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.